Stockscreener 앱 받기
4.90
0.81%
-0.04
전일 마감가:
$4.94
열려 있는:
$5.1
하루 거래량:
7.34M
Relative Volume:
2.79
시가총액:
$802.83M
수익:
-
순이익/손실:
$-196.48M
주가수익비율:
-4.0303
EPS:
-1.2158
순현금흐름:
$-183.16M
1주 성능:
+4.26%
1개월 성능:
-1.21%
6개월 성능:
+1.66%
1년 성능:
+109.40%
1일 변동 폭
$4.815
$5.21
1주일 범위
$4.46
$5.21
52주 변동 폭
$1.85
$7.18
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650) 822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.90 | 802.83M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Annexon unveils six Guillain-Barre syndrome studies at PNS2026 global forum - Traders Union
ANNX News | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Inc (ANNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annexon Inc (ANNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annexon Inc (ANNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annexon Inc (ANNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annexon Inc (ANNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annexon Inc (ANNX) Institutional Confidence - TradingKey
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annexon Inc (ANNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANNX Stock Price, Quote & Chart - ChartMill
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Two new Annexon hires receive options on 705,000 shares - Stock Titan
Annexon (ANNX) director William Waddill receives 65,000 stock options grant - Stock Titan
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant - Stock Titan
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70 - Stock Titan
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares - Stock Titan
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEarnings Sentiment Score - newsline.com
Annexon Inc. (ANNX) Holds Steady Near Support as Biotech Sector Faces HeadwindsRisk Parity Rebalance - newsline.com
Annexon Stockholders Approve Directors, Compensation and Share Increase - TipRanks
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes - Stock Titan
Annexon Inc. (ANNX) Gains 2.13% as Biotech Stock Holds Above Key SupportCounter Trend Trade - newsline.com
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027 - TradingView
Annexon Inc Annual Shareholders Meeting Transcript - GuruFocus
Annexon eyes 'win season' with Q4 vision trial data, GBS filings ahead - MSN
Annexon maps 3 big pipeline catalysts ahead of Q4 vision-drug readout - MSN
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead - MarketBeat
Annexon Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - sharewise.com
ANNX: Three major clinical data readouts expected in 2024, each with strong differentiation - TradingView
Annexon Inc. (ANNX) Holds Steady Near Support as Consolidation ContinuesBeta Neutral Pair - newsline.com
ANNX Q1 2026 Earnings: EPS Beat Guidance as Clinical Progress ContinuesSubscription Growth Report - The Legal Advocate
Annexon(ANNX.US) Director Buys US$3.32 Million in Common Stock - Moomoo
Annexon Inc. (ANNX) Shows Modest Gain: Biotech Stock Tests Key LevelsWide Range Bar - The Legal Advocate
Insider Purchase: Director at $ANNX Buys 613,497 Shares - Moomoo
Annexon director Muneer Satter buys $3.3m in common stock By Investing.com - Investing.com South Africa
Annexon director Muneer Satter buys $3.3m in common stock - Investing.com
Director-linked fund buys 613K Annexon (ANNX) shares in open market - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageCFO Commentary Report - The Legal Advocate
ANNX Q1 2026 Earnings: EPS Surpasses Estimates by 22% as Biotech Advances PipelineEarnings Preview - The Legal Advocate
ANNX Q1 2026 Earnings: EPS Beat Surprise as Clinical-Stage Biotech Tightens Cost ControlPost-Earnings Drift - newsline.com
Annexon to Participate in Upcoming June Investor Conferences - Investing News Network
Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Lifts Shares as Pre-Revenue Biotech AdvancesEarnings Revision Report - newsline.com
ANNX Q1 2026 Earnings: Clinical Pipeline Progress Drives EPS Beat as Stock Dips on Broader Biotech HeadwindsGuidance Accuracy Score - newsline.com
Annexon Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):